XENE - ゼノン・ファ―マシュ―ティカルズ （Xenon Pharmaceuticals Inc.）

BURNABY, British Columbia, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, August 9, 2022.

Despite its recent outperformance, the shares of Xenon Pharmaceuticals (XENE) could offer further upside, JP Morgan argued on Thursday, adding the Canadian biotech to the firm’s…

https://www.investing.com/news/pro/jpmorgan-starts-xenon-pharmaceuticals-at-overweight-432SI-2850311

Applied Therapeutics APLT -22% on pricing $30M equity offering.Xenon Pharmaceuticals XENE -13% on pricing $250M equity offering.Clovis Oncology (CLVS) -10% Zai Lab (ZLAB) -9% on…

Clinical-stage biotech Xenon Pharmaceuticals (XENE) dropped ~11% in the post-market Wednesday after the company announced an underwritten public offering of its common stock.A decision…

BURNABY, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conference to be held June 8-10, 2022 in New York, NY.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) price on Friday, May 27, rose 3.58% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $27.49. A look at the stock’s price movement, the close in the last trading session was $26.54, moving within a range at $26.12 and $27.86. The beta value … Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Could Be Worth Considering Read More »

XEN1101 “End of Phase 2” Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022

Xenon Pharmaceuticals (XENE) is scheduled to announce Q1 earnings results on Tuesday, May 10, after market close.The consensus EPS estimate is -$0.40 and the consensus revenue estimate…

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) price on Friday, May 06, fall -3.68% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $27.23. A look at the stock’s price movement, the close in the last trading session was $28.27, moving within a range at $26.16 and $27.85. The beta value … Xenon Pharmaceuticals Inc. (XENE): Is It Worth A Small Bite At $27.23? Read More »

Conference Call at 4:30 pm ET Today Conference Call at 4:30 pm ET Today

Dealreporter flags Xenon Pharmaceuticals <> as a potential acquisition target following the agreement between Zogenix <> and UCB under which the Belgian drugmaker offered

Xenon Pharmaceuticals (XENE) reaches regulatory milestone to receive a payment of $15M from Neurocrine Biosciences (NBIX) under its collaboration to develop treatments for epilepsy. It

Brokerages expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to announce earnings of ($0.42) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Xenon Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.67). Xenon Pharmaceuticals reported earnings of ($0.34) per []